All News

2022

July

Media Release / Jul 25, 2022

Applications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab accepted by US FDA and EMA

Read More
Media Release / Jul 21, 2022

Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF)

Read More
Media Release / Jul 19, 2022

Novartis delivers continued strong momentum of key growth brands, progress on strategic initiatives and confirms FY’22 Group guidance

Read More

June

Media Release / Jun 17, 2022

Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA

Read More
Media Release / Jun 10, 2022

HEXAL launches Dimethyl fumarate HEXAL® a generic drug for Tecfidera®, in Germany, offering an economically efficient treatment option for the care of adult patients with multiple sclerosis*

Read More
Living with MS
Featured News / Jun 07, 2022

Living with Multiple Sclerosis (MS) – A disease with 1000 faces

Read More

May

Media Release / May 31, 2022

Sandoz announces new global ‘Act4Biosimilars’ initiative, to improve patient access and increase adoption by at least 30% in 30+ countries by 2030

Read More
Media Release / May 27, 2022

Sandoz appoints new Board representative to global AMR Industry Alliance

Read More
Media Release / May 12, 2022

Sandoz launches first generic pirfenidone in US for patients with idiopathic pulmonary fibrosis, growing its respiratory portfolio

Read More

April

Media Release / Apr 26, 2022

Novartis delivers solid sales and profit growth. Strong performance of in-market brands supports confidence in mid-term growth outlook

Read More